P
Patrick Avenet
Publications - 32
Citations - 1864
Patrick Avenet is an academic researcher. The author has contributed to research in topics: NMDA receptor & Receptor. The author has an hindex of 21, co-authored 32 publications receiving 1782 citations.
Papers
More filters
Journal ArticleDOI
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
Philippe Pichat,Olivier Bergis,Terranova Jean-Paul,Alexandre Urani,Christine Duarte,Vincent Santucci,Christiane Gueudet,Carole Voltz,Régis Steinberg,Jeanne Stemmelin,F. Oury-Donat,Patrick Avenet,Guy Griebel,Bernard Scatton +13 more
TL;DR: Findings characterize SSR180711 as a promising new agent for the treatment of cognitive symptoms of schizophrenia and the antidepressant-like properties of SSR 180711 are of added interest, considering the high prevalence of depressive symptoms in schizophrenic patients.
Journal ArticleDOI
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Ronan Depoortère,Gihad Dargazanli,Genevieve Estenne-Bouhtou,Annick Coste,Christophe Lanneau,C. Desvignes,Martine Poncelet,Michel Heaulme,Vincent Santucci,Michel Decobert,Annie Cudennec,Carolle Voltz,Denis Boulay,Jean Paul Terranova,Jeanne Stemmelin,Pierre Roger,Benoit Marabout,Mireille Sevrin,Xavier Vigé,Bruno Biton,Régis Steinberg,Dominique Françon,R. Alonso,Patrick Avenet,F. Oury-Donat,Ghislaine Perrault,Guy Griebel,Pascal George,Philippe Soubrie,Bernard Scatton +29 more
TL;DR: SSR504734 is a potent and selective GlyT1 inhibitor, exhibiting activity in schizophrenia, anxiety and depression models, and is expected to be efficacious not only against positive but also negative symptoms, cognitive deficits, and comorbid depression/anxiety states.
Journal ArticleDOI
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
Bruno Biton,Olivier Bergis,Frederic Galli,Alain Nedelec,Alistair Lochead,Samir Jegham,Danielle Godet,Christophe Lanneau,Raphaël Santamaria,Francoise Chesney,Jacques Léonardon,Patrick Granger,Marc Williams Debono,Georg Andrees Bohme,Frédéric Sgard,François Besnard,David I. Graham,Annick Coste,André Oblin,Olivier Curet,Xavier Vigé,Corinne Voltz,Liliane Rouquier,Josiane Souilhac,Vincent Santucci,Christiane Gueudet,Dominique Françon,Régis Steinberg,Guy Griebel,F. Oury-Donat,Pascal George,Patrick Avenet,Bernard Scatton +32 more
TL;DR: It is demonstrated that SSR180711 is a selective and partial agonist at human, rat and mouse α7 n-AChRs, increasing glutamatergic neurotransmission, ACh release and LTP in the hippocampus.
Journal ArticleDOI
SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation
Caroline Cohen,Olivier Bergis,Frederic Galli,Alister W. Lochead,Samir Jegham,Bruno Biton,Jacques Léonardon,Patrick Avenet,Frédéric Sgard,François Besnard,David I. Graham,Annick Coste,André Oblin,Olivier Curet,Carole Voltz,Arlette Gardes,Dominique Caille,Ghislaine Perrault,Pascal George,Philippe Soubrie,Bernard Scatton +20 more
TL;DR: The present results confirm important role for α4β2 nAChRs in mediating nicotine dependence and suggest that SSR591813, a partial agonist at this particular nA ChR subtype, may have therapeutic potential in the clinical management of smoking cessation.
Journal ArticleDOI
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
Jeanne Stemmelin,Caroline Cohen,Terranova Jean-Paul,Matilde Lopez-Grancha,Philippe Pichat,Olivier Bergis,Michel Decobert,Vincent Santucci,Dominique Françon,R. Alonso,Stephen M. Stahl,P.E. Keane,Patrick Avenet,Bernard Scatton,Gérard Le Fur,Guy Griebel +15 more
TL;DR: It is demonstrated for the first time that the stimulation of the β3 receptor by SR58611A resulted in robust anxiolytic-like effects, which paralleled those obtained with the prototypical benzodiazepine anxIOlytic diazepam or chlordiazepoxide.